Open prospective study to evaluate the efficacy of a new vaginal pessary containing 300mg tinidazole, 200mg tioconazole and 100mg lidocaine with a 3-day regime (Gynomax XL®) in the treatment of vaginal infections due to bacterial vaginosis, candidiasis an

Abstract

Introduction. The management of infections of the vulva and vagina depend on the selection and administration of effective specific therapies that allow a fast treatment, enhancing the compliance of the patients. Objective of the study: the efficacy and safety of a new medicinal product containing 300mg tinidazole/200mg tioconazole/100mg lidocaine for the treatment against vaginal candida albicans, bacterial vaginosis and combined infections was evaluated upon 69 patients. Materials and methods. Clinical controls, pH, 10% KOH probe, microscopical and microbiological analysis were performed at day 1, day 4, day 10 and at day 30 of the study. Success was defined as follows: 0 points = no symptoms, 1 point = mild symptoms, 2 points = moderate symptoms, 3 points = severe symptoms. Results. A complete clinical recovery at day 10 was observed in 54 (80.6%) patients. A clinical improvement in 12 (17.9%) and a failure in 1 patient (1,5%). At day 30 a clinical complete recovery was observed in 58 (86.6%) patients, a clinical improvement in 7 (10.4%) and a failure in 2 patients (3%). Conclusions. This formulation (GynomaxXL), a vaginal suppository given at 3 consecutive days, is a highly effective and safe combination in the therapy of vulvovaginal candidiasis and bacterial vaginosis.

Keywords

• candidiasis
• bacterial vaginosis
• mixed vaginal infections
• tinidazole
• tioconazol